Truist Securities Reiterates Buy on Regeneron Pharmaceuticals, Raises Price Target to $1200
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has reiterated its Buy rating on Regeneron Pharmaceuticals and raised the price target from $1135 to $1200.
August 02, 2024 | 1:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities has reiterated its Buy rating on Regeneron Pharmaceuticals and raised the price target from $1135 to $1200.
The reiteration of a Buy rating and an increased price target from a reputable analyst can positively influence investor sentiment and potentially drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100